Transcode Therapeutics’ TTX-MC138 Is in Phase 2a Development
Transcode Therapeutics says its lead program, TTX-MC138, is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX — MC138 in Colorectal Cancer
For best results when printing this announcement, please click on link below: Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. ( ) (Nasdaq: NTRA), a global leader in c